---
company: OptimizeRx Corp
ticker: OPRX
form: 8-K
filed: 2026-05-12
accession: 0001448431-26-000009
source: https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/
---

# OptimizeRx (OPRX) earnings release, May 12, 2026

OptimizeRx Corp (OPRX) · Form 8-K, Item 2.02 · Filed 2026-05-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/)

OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

-

Q1 revenue totals $19.8 million

-

Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively

-

2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million

-

Paid off an incremental $2.7 million in principal from term loan during Q1

-

Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings

-

Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026

WALTHAM, MA. – May 12, 2026 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended March 31, 2026.

Financial Highlights

• Revenue in the first quarter of 2026 decreased 10% to $19.8 million when compared to $21.9 million in the same year ago period.

• GAAP net loss in the first quarter of 2026 narrowed to $(0.5) million, or $(0.03) per share, compared to net loss of $(2.2) million, or $(0.12) per share, in the same period of 2025.

• Non-GAAP net income in the first quarter of 2026 increased to $2.7 million, or $0.14 per diluted share, compared to Non-GAAP net income of $1.5 million, or $0.08 per diluted share, in the same period of 2025. (see *

Non-GAAP Measures below)

• Adjusted EBITDA for the first quarter of 2026 increased to $3.3 million compared to $1.5 million in the same year ago period. (see *

Non-GAAP Measures below)

• Cash and cash equivalents totaled $20.2 million as of March 31, 2026 as compared to $23.4 million as of December 31, 2025.

• Paid off $2.7 million of principal and exited the first quarter of 2026 with $23.6 million in debt.

• Subsequent to the end of the quarter, the Company refinanced its debt through Fifth Third Bank which lowers the interest rate by 625 basis points, an annual interest expense savings of approximately $1.5 million, through a $25 million term loan and an undrawn $10 million revolver.

Stephen Silvestro, OptimizeRx CEO commented, “We delivered a solid start to 2026, exceeding consensus for the quarter, reinforcing the strength and resilience of our operating model. While we are seeing some short to intermediate term disruption from ongoing most favored nations (MFN) pricing dynamics and other macroeconomic factors leading to more measured customer spending, we do not view these pressures as enduring obstacles.

“Importantly, the long-term shift toward digital, data-driven engagement across life sciences remains firmly intact and continues to provide a meaningful driver for our business. We are encouraged by the traction we are seeing with existing customers, particularly in instances where they are not directly impacted by MFN, and with mid-tier and emerging clients. As recently announced, we are also expanding our platform capabilities by opening our proprietary electronic health record network to demand-side platforms (DSPs), enabling media buyers to activate scalable, point of care campaigns within their clinical programmatic workflow. Providing programmatic access to DSPs will position us to significantly increase inventory utilization and unlock a new, high-growth revenue channel over time. We believe our differentiated network, deep integrations, and scalable model position us to capitalize on the significant long-term opportunity in front of us.”

2026 Financial Outlook

The Company is updating its fiscal year 2026 guidance, and now expects revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million.

Conference Call, Webcast, and Webcast Replay Information

Date: Tuesday, May 12, 2026

Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Toll Free: 1-877-407-9716

International: 1-201-493-6779

Conference ID: 13760191

Call Me

: https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6

Webcast

: https://viavid.webcasts.com/starthere.jsp?ei=1760247&tp_key=80ee98d522

Webcast Replay:

The archived webcast will be on the investor relations section of the OptimizeRx website

Individual Meeting Invitation

In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or dfarrell@lifesciadvisors.com.

*Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.

Although the Company provides guidance for adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.... (tition of Key Performance Indicators

Top 20 pharmaceutical manufacturers:

We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2025 revenue”. We previously used “The top 20 pharma companies by 2024 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention

: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average full-time employee:

We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected adjusted EBITDA, ability to reinforce the strength and resilience of the Company’s operating model, macroeconomics factors not expected to be enduring disruptions, digital, data-driven engagement remaining intact and continuing to be a meaningful driver for the business, current and future traction with existing and new customers, plans to successfully launch programmatic access to the Company’s authenticated EHR network, programmatic access will increase inventory utilization and unlock high-growth revenue channel, ability to capitalize on significant long-term opportunity, plans to grow shareholder value creation, plans to continue the Company’s growth and transformation, plans to position the Company to become a sustained “Rule of 40” company, increased market volatility, engagement across the Company’s network, , and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on

Form 10-K for the fiscal year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact

Andy D’Silva, Chief Business Officer adsilva@optimizerx.com

Investor Relations Contact

Douglas Farrell

LifeSci Advisors, LLC dfarrell@lifesciadvisors.com

## Financial statements

### Income Statement (Rolling Twelve Months Ended March 31, (in thousands, except percentages))

| | Rolling Twelve Months Ended March 31, – 2026 | Rolling Twelve Months Ended March 31, – 2025 |
|---|---:|---:|
| Average revenue per top 20 pharmaceutical manufacturers | 2,791 | 2,963 |
| Percent of total revenue attributable to top 20 pharmaceutical manufacturers | 52 | 63 |
| Net revenue retention | 110 | 114 |
| Revenue per average full-time employee | 801 | 710 |

### Income Statement (For the Three Months Ended March 31, — (in thousands, except share and per share data, unaudited))

| | For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Net revenue | 19,844 | 21,928 |
| Expenses | Cost of revenues, exclusive of depreciation and amortization presented separately below | 4,912 | 8,584 |
| Expenses | Sales and marketing | 4,729 | 4,985 |
| Expenses | General and administrative expenses | 3,513 | 4,557 |
| Expenses | Research and development | 3,402 | 3,252 |
| Expenses | Stock-based compensation | 1,828 | 1,558 |
| Expenses | Depreciation and amortization | 1,064 | 1,094 |
| Expenses | Total expenses | 19,448 | 24,030 |
| Expenses | Income (loss) from operations | 396 | -2,102 |
| Other income (expense) | Interest expense | -1,155 | -1,297 |
| Other income (expense) | Other income | 38 | 39 |
| Other income (expense) | Interest income | 77 | 88 |
| Other income (expense) | Total other expenses, net | -1,040 | -1,170 |
| Other income (expense) | Loss before provision for income taxes | -644 | -3,272 |
| Other income (expense) | Income tax benefit | 149 | 1,073 |
| Other income (expense) | Net loss | -495 | -2,199 |
| Other income (expense) | Weighted average number of shares outstanding – basic | 18,761,622 | 18,470,808 |
| Other income (expense) | Weighted average number of shares outstanding – diluted | 18,761,622 | 18,470,808 |
| Other income (expense) | Loss per share – basic | -0.03 | -0.12 |
| Other income (expense) | Loss per share – diluted | -0.03 | -0.12 |

### Income Statement (Three Months Ended March 31,)

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Net loss | -495 | -2,199 |
| Depreciation and amortization | 1,064 | 1,094 |
| Stock-based compensation | 1,828 | 1,558 |
| Severance expenses | 30 | 275 |
| Shareholder activist related fees |  | 451 |
| CEO search fees |  | 225 |
| Other income | -38 | -39 |
| Amortization of debt issuance costs | 358 | 174 |
| Non-GAAP net income | 2,747 | 1,539 |
| Non-GAAP net income per share | Diluted | 0.14 | 0.08 |
| Weighted average shares outstanding: | Diluted | 19,107,036 | 18,579,012 |

### Income Statement (Three Months Ended March 31,)

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Net loss | -495 | -2,199 |
| Depreciation and amortization | 1,064 | 1,094 |
| Income tax benefit | -149 | -1,073 |
| Stock-based compensation | 1,828 | 1,558 |
| Severance expenses | 30 | 275 |
| Shareholder activist related fees |  | 451 |
| CEO search fees |  | 225 |
| Other income | -38 | -39 |
| Interest expense, net | 1,078 | 1,209 |
| Adjusted EBITDA | 3,318 | 1,501 |

### Balance Sheet ((in thousands, except share and per share data))

| | March 31, 2026 – (unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 20,169 | 23,365 |
| Current assets | Accounts receivable, net of allowance for credit losses of $260 at March 31, 2026 and December 31, 2025 | 31,989 | 37,752 |
| Current assets | Taxes receivable | 871 | 752 |
| Current assets | Prepaid expenses and other | 3,136 | 2,846 |
| Current assets | Total current assets | 56,165 | 64,715 |
| Current assets | Property and equipment, net | 107 | 106 |
| Other assets | Goodwill | 70,869 | 70,869 |
| Other assets | Patent rights, net | 4,426 | 4,586 |
| Other assets | Technology assets, net | 6,576 | 6,870 |
| Other assets | Tradename and customer relationships, net | 28,751 | 29,340 |
| Other assets | Operating lease right-of-use assets | 352 | 404 |
| Other assets | Security deposits and other assets | 18 | 28 |
| Other assets | Total other assets | 110,992 | 112,097 |
| Other assets | TOTAL ASSETS | 167,264 | 176,918 |
| Current liabilities | Current portion of long-term debt | 2,000 | 4,255 |
| Current liabilities | Accounts payable | 3,066 | 1,636 |
| Current liabilities | Accrued expenses | 3,592 | 11,591 |
| Current liabilities | Revenue share payable | 955 | 3,086 |
| Current liabilities | Current portion of lease liabilities | 177 | 193 |
| Current liabilities | Deferred revenue | 669 | 503 |
| Current liabilities | Total current liabilities | 10,459 | 21,264 |
| Non-current liabilities | Long-term debt, net | 21,343 | 21,421 |
| Non-current liabilities | Lease liabilities, net of current portion | 196 | 234 |
| Non-current liabilities | Deferred tax liabilities, net | 5,655 | 5,705 |
| Non-current liabilities | Total liabilities | 37,653 | 48,624 |
| Stockholders’ equity | Common stock, $0.001 par value, 166,666,667 shares authorized, 20,506,472 and 20,500,986 shares issued at March 31, 2026 and December 31, 2025, respectively | 21 | 20 |
| Stockholders’ equity | Treasury stock, $0.001 par value, 1,741,397 shares held at March 31, 2026 and December 31, 2025 | -2 | -2 |
| Stockholders’ equity | Additional paid-in-capital | 209,323 | 207,512 |
| Stockholders’ equity | Accumulated deficit | -79,731 | -79,236 |
| Stockholders’ equity | Total stockholders’ equity | 129,611 | 128,294 |
| Stockholders’ equity | TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 167,264 | 176,918 |

### Cash Flow (For the Three Months Ended March 31, — (in thousands, unaudited))

| | For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 |
|---|---:|---:|
| OPERATING ACTIVITIES: | Net loss | -495 | -2,199 |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | Depreciation and amortization | 1,064 | 1,094 |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | Stock-based compensation | 1,828 | 1,558 |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | Amortization of debt issuance costs | 358 | 174 |
| Changes in: | Accounts receivable | 5,763 | 5,492 |
